Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality

During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.

More from Archive

More from Pink Sheet